Member Info for Danielm89

No trolls today… interesting 🧐

Spreading the word, let’s stop cancer together ❤️

🚀 Big news! Cizzle Bio is expanding into the U.S. market with our groundbreaking CIZ1B biomarker test for early lung cancer detection.

Partnerships, FDA approvals, and a 2025 launch are all in the works.

Watch Dr. Syms discuss the journey ahead: buff.ly/3NDzdYE

Https://finance.yahoo.com/news/cavendish-financial-leads-3-promising-090802663.html

Cizzle Biotechnology Holdings

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Cizzle Biotechnology Holdings Plc, along with its subsidiaries, focuses on developing an immunoassay test for the CIZ1B cancer biomarker aimed at early lung cancer detection in the United Kingdom, with a market cap of £7.53 million.

Operations: Cizzle Biotechnology Holdings Plc has not reported any revenue segments.

Market Cap: £7.53M

Cizzle Biotechnology Holdings, with a market cap of £7.53 million, is pre-revenue and focuses on developing a lung cancer detection test. Despite being unprofitable with increased losses over the past five years, it remains debt-free and has sufficient cash runway for over a year. Recent strategic moves include expanding its licensing agreement to cover North America and the Caribbean, potentially accelerating revenue generation through early royalty payments from Cizzle Bio Inc. The appointment of Professor Dawn Coverley as Chief Scientific Officer aims to bolster partnerships and support technical advancements for global scalability of its biomarker assay test.

🤔 posted yesterday

Https://finance.yahoo.com/news/cavendish-financial-leads-3-promising-090802663.html

Cizzle Biotechnology Holdings

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Cizzle Biotechnology Holdings Plc, along with its subsidiaries, focuses on developing an immunoassay test for the CIZ1B cancer biomarker aimed at early lung cancer detection in the United Kingdom, with a market cap of £7.53 million.

Operations: Cizzle Biotechnology Holdings Plc has not reported any revenue segments.

Market Cap: £7.53M

Cizzle Biotechnology Holdings, with a market cap of £7.53 million, is pre-revenue and focuses on developing a lung cancer detection test. Despite being unprofitable with increased losses over the past five years, it remains debt-free and has sufficient cash runway for over a year. Recent strategic moves include expanding its licensing agreement to cover North America and the Caribbean, potentially accelerating revenue generation through early royalty payments from Cizzle Bio Inc. The appointment of Professor Dawn Coverley as Chief Scientific Officer aims to bolster partnerships and support technical advancements for global scalability of its biomarker assay test.

🤔 posted yesterday

Https://finance.yahoo.com/news/cavendish-financial-leads-3-promising-090802663.html

Cizzle Biotechnology Holdings

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Cizzle Biotechnology Holdings Plc, along with its subsidiaries, focuses on developing an immunoassay test for the CIZ1B cancer biomarker aimed at early lung cancer detection in the United Kingdom, with a market cap of £7.53 million.

Operations: Cizzle Biotechnology Holdings Plc has not reported any revenue segments.

Market Cap: £7.53M

Cizzle Biotechnology Holdings, with a market cap of £7.53 million, is pre-revenue and focuses on developing a lung cancer detection test. Despite being unprofitable with increased losses over the past five years, it remains debt-free and has sufficient cash runway for over a year. Recent strategic moves include expanding its licensing agreement to cover North America and the Caribbean, potentially accelerating revenue generation through early royalty payments from Cizzle Bio Inc. The appointment of Professor Dawn Coverley as Chief Scientific Officer aims to bolster partnerships and support technical advancements for global scalability of its biomarker assay test.

🤔 posted yesterday

From the company twitter

We are taking deliberate steps to enhance market awareness and encourage investor participation during this exciting time for CEG. These efforts are showing early results, as we have observed upward momentum in recent weeks.

“Substantial news flow”

3 minutes in

Put the link on Twitter won’t work here

https://x.com/theunsophistic2/status/1876961780947095868?s=46&t=4s-AQzZhMmeWz3Ire1AEsA

new interview out

challenger energy group plc

i don’t normally comment on eytan’s letters but i do commend this to all shareholders but perhaps more importantly those who have yet to take the plunge. with chevron signed, sealed and more importantly paid up for area off-1 and the recent addition to the shareholder list of charleston things are indeed looking positive. 

next stop area off-3 and the technical data, there is no reason to believe that the company cannot repeat the exercise and that makes challenger a very exciting play indeed, watch this space.

https://www.***************************/challenger-energy-plc-transforming-exploration-potential-into-a-frontier-opportunity/4121182843

Cizzle’s new lung cancer biomarker, CIZ1B

The biomarker means that there is now the potential for a simple blood test to be used in early detection of lung cancer, reducing the reliance on CT scans

This is a gold-standard test of what the biomarker can do, which we hope will help pave the way for its use in UK hospitals in the future

“BIO has executed its first and confidential agreement with a CAP approved clinical laboratory and intends to register the CIZ1B biomarker as a CLIA accredited test in January 2025 with plans for commercial launch in April 2025”

https://www.york.ac.uk/news-and-events/news/2024/research/blood-test-lung-cancer/

Cizzle’s new lung cancer biomarker, CIZ1B

The biomarker means that there is now the potential for a simple blood test to be used in early detection of lung cancer, reducing the reliance on CT scans

This is a gold-standard test of what the biomarker can do, which we hope will help pave the way for its use in UK hospitals in the future

“BIO has executed its first and confidential agreement with a CAP approved clinical laboratory and intends to register the CIZ1B biomarker as a CLIA accredited test in January 2025 with plans for commercial launch in April 2025”

https://www.york.ac.uk/news-and-events/news/2024/research/blood-test-lung-cancer/

Only 500k of sells… try again

£2500 is 1.94 £5000 1.97

£6000 nt

Https://x.com/theunsophistic2/status/1876626725414781155?s=12&t=4s-AQzZhMmeWz3Ire1AEsA

Bit of background

Lung cancer is the biggest killer of the cancers,

Why big d?

Because you only realise when you cough blood (symptomatic) this is stage 3

What’s stage 3 big d?

10% survival, unfortunately p10

Ciz1b can be detected at stage 1, a grain of rice cancer simple operation

But what about scans big d?

Ultrasound, mri, ct scan … £10k… and still don’t know until swabbed. CIZ test £50-100 lateral flow 10 minutes

Someone paid 9m for Cory 😉

Https://www.londonstockexchange.com/news-article/CEG/2024-year-end-letter-to-shareholders/16839899

Trinidad & The Bahamas

We are currently reviewing our assets in Trinidad and The Bahamas, and anticipate making a decision on their future in the first half of 2025.

Read like a sale to me …..

Trinidad will be worth about what ? 10-20m?

Https://www.youtube.com/watch?v=f_Hpe6xgK5U

3.08-3.40

Some interesting and very positive results from off 3

Nt to buy again

We should hear something soon on the recent interview he said the data coming back on off 3 is looking very very good